4.7 Article

Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study

Journal

LANCET INFECTIOUS DISEASES
Volume 20, Issue 3, Pages 308-317

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(19)30550-X

Keywords

-

Funding

  1. National Institute of Neurologic Disorders and Stroke [R01NS086312, K23NS110470]
  2. Fogarty International Center [K01TW010268, K43TW010718]
  3. National Institute of Allergy and Infectious Diseases [T32AI055433]
  4. Wellcome Trust [210772/Z/18/Z, 107743]
  5. Developing Excellence in Leadership, Training and Science Africa Initiative [107743]
  6. African Academy of Sciences
  7. Alliance for Accelerating Excellence in Science in Africa
  8. New Partnership for Africa's Development Planning and Coordinating Agency
  9. UK Government
  10. UK MRC
  11. UK Department for International Development (DFID) under the MRC/DFID Concordat agreement
  12. EU
  13. MRC [MR/R010161/1, MC_UP_1204/15, MC_UU_00027/5] Funding Source: UKRI
  14. Wellcome Trust [210772/Z/18/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Introduction Tuberculous meningitis accounts for 1-5% of tuberculosis cases. Diagnostic delay contributes to poor outcomes. We evaluated the performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis diagnosis. Methods In this prospective validation study, we tested the cerebrospinal fluid (CSF) of adults presenting with suspected meningitis (ie, headache or altered mental status with clinical signs of rneningism) to the Mulago National Referral Hospital and Mbarara Regional Referral Hospital in Uganda. We centrifuged the CSF, resuspended the cell pellet in 2 mL CSF, and tested 0.5 mL aliquots with Xpert Ultra, Xpert MTB/RIF (Xpert), and mycobacterial growth indicator tube (MGIT) culture. We quantified diagnostic performance against the uniform case definition of probable or definite tuberculous meningitis and a composite microbiological reference standard. Findings From Nov 25,2016, to Jan 24,2019, we screened 466 adults with suspected meningitis and tested 204 for tuberculous meningitis. Uniform clinical case definition classified 51 participants as having probable or definite tuberculous meningitis. Against this uniform case definition, Xpert Ultra had 76.5% sensitivity (95% CI 62.5-87.2; 39 of 51 patients) and a negative predictive value of 92.7% (87.6-96.2; 153 of 165), compared with 55.6% sensitivity (44.0-70.4; 25 of 45; p=0.0010) and a negative predictive value of 85.8% (78.9-91.1; 121 of 141) for Xpert and 61.4% sensitivity (45.5-75.6; 27 of 44; p=0.020) and negative predictive value of 85.2% (77.4-914; 98 of 115) for MGIT culture. Against the composite microbiological reference standard, Xpert Ultra had sensitivity of 92.9% (80.5-98.5; 39 of 42), higher than Xpert at 65.8% (48.6-80.4; 25 of 38; p=0.0063) and MGIT culture at 72.2% (55.9-86.2; 27 of 37; p=0.092). Xpert Ultra detected nine tuberculous meningitis cases missed by Xpert and MGIT culture. Interpretation Xpert Ultra detected tuberculous meningitis with higher sensitivity than Xpert and MGIT culture in this HIV-positive population. However, with a negative predictive value of 93%, Xpert Ultra cannot be used as a rule-out test. Clinical judgment and novel highly sensitive point-of-care tests are still required. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available